Intel 14A Defect Density Best Since 22nm, Says CFO
By @sharedot · · 7 pages
- Tech
- Intel
- Semiconductors
- 14a
- Foundry
CFO David Zinsner says Intel 14A defect density is beating its target curve faster than any node since 22nm, with customers now asking about capacity.
What happened
"It is also doing better than any of the previous nodes in terms of how quickly we are bringing down the defects. In fact, we have not seen this performance since 22nm, which is arguably one of the best nodes Intel has ever put out," Zinsner said.
Intel plans risk production of 14A products in the second half of 2027 and high-volume manufacturing in 2028.
Why it is surprising
The comparison to 22nm carries weight because the nodes that followed it struggled: 14nm mass production was delayed by a year over insufficient yield, the first 10nm node failed, 20A was cancelled, and 18A defect density remained high even as it hit its high-volume manufacturing milestone.
A statement that 14A's defect reduction is the healthiest since 22nm is a notable reversal from Intel's recent track record, especially since the company has shared little about progress on Intel 4 and Intel 3.
Igor'sLAB notes that after the 10nm problems and the 20A cancellation, Intel has reason to be cautious about comparisons to its own heyday, which makes the CFO's claim all the more striking.
The evidence — and its caveats
The claim is specifically about the speed of defect reduction at a comparable point in development, roughly two years before mass production, not that 14A already matches 22nm's absolute defect levels or yield.
Tom's Hardware cautions that what Intel counts as a defect now may differ from 2010, due to advances in wafer processing and inspection equipment, and that defect density does not directly equal product yield — actual yield also depends on chip size, design, and defect type and distribution.
According to Igor'sLAB, 14A targets 15–20% more performance at the same power versus 18A, or 25–35% lower power at the same performance, plus up to 30% higher density; these are Intel's internal targets, not measurements of finished chips.
The stakes
The foundry business is the core stake. According to Igor'sLAB, Intel disclosed in its 2025 annual report that it might have to pause or discontinue 14A and subsequent nodes if it could not secure a significant external foundry customer, given the capital intensity of leading-edge manufacturing.
Zinsner said internal Intel design teams — "probably the most cynical bunch out of anybody" — are now designing products on 14A, and that external engagements have significantly increased, with CEO Lip-Bu Tan meeting customers weekly.
According to International Business Times AU, customers have moved from reviewing technical data to asking how much capacity and supply Intel can provide. Still, no major binding external 14A contract has been announced.
What comes next
According to International Business Times AU, Intel's 0.9 process design kit for 14A — the toolset chip designers use to build products for the node — is expected in October, with risk production planned for 2027 and high-volume manufacturing targeted for 2028.
The company also raised its 2026 capital expenditure guidance to $20 billion, after a roughly $23 billion equity offering, and said its existing 18A process is yielding ahead of internal targets, per the same report.
Capacity expansions are planned across multiple facilities, including more than doubling output at Fab 52 in Ireland next year and accelerating Fab 62 in Arizona.
Whether 14A becomes the turning point Intel needs will rest on functioning customer chips, reliable yields, and binding foundry contracts.
Sources
- tomshardware.com › Intel 14A defect density is dropping faster than the company expected — 'we have not seen this performance since 22nm,' says CFO
- igorslab.de › Intel 14A: Defect Density Better Than Planned
- ibtimes.com.au › Intel Says 14A Chip Defect Reduction Is Its Best Progress Since the 22nm Process, CFO Tells Investors